What is Kiniksa Pharmaceuticals International, plc's (KNSA) StockRank?

MoatMap's StockRank for Kiniksa Pharmaceuticals International, plc (KNSA) is 87/100, with a Strong Buy signal. This is a composite score combining Quality (83), Value (20), and Momentum (79) factor ranks across MoatMap's 20,000+ stock universe.

Does Kiniksa Pharmaceuticals International, plc have an economic moat?

Kiniksa Pharmaceuticals International, plc (KNSA) has a Quality factor score of 83/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is Kiniksa Pharmaceuticals International, plc a buy, hold, or sell?

MoatMap's current signal for Kiniksa Pharmaceuticals International, plc (KNSA) is Strong Buy, based on a StockRank of 87/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.

What sector is Kiniksa Pharmaceuticals International, plc in?

Kiniksa Pharmaceuticals International, plc (KNSA) operates in the Healthcare sector, specifically the Drug Manufacturers - Specialty & Generic industry (United Kingdom).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

KNSA

STRONG BUYFLAG

Kiniksa Pharmaceuticals International, plc · Healthcare · United Kingdom · $4.8B · Avg Vol: $56M/d

StockRank

Get insider-trade alerts

P/E (TTM)

70.3x

ROE

13.7%

D/E

0.0x

Dividend %

—

AI CONVICTION THESIS

Kiniksa Pharmaceuticals has strong quality Q83 and momentum M83, but value at V20 is the lowest in this batch and far below the calibrated floor. Insider selling of 0.23% is separately adverse.

COMPANY DESCRIPTION

Kiniksa Pharmaceuticals International, plc is a biopharmaceutical company dedicated to discovering, developing, and commercializing innovative therapeutics for patients with debilitating rare diseases. The company's strategic focus on underserved inflammatory and autoimmune conditions provides potential for orphan drug exclusivity, offering a strong competitive moat. Kiniksa aims to become a leader in developing targeted treatments for these specific, high-unmet-need patient populations.

FINANCIAL SUMMARY (USD)

Year	2021	2022	2023	2024	2025	CAGR	TTM	2026E	2027E	Fwd CAGR
Revenue	—	220.2M	270.3M	423.2M	677.6M	45.5%	754.0M	940.1M	1.1B	29.5%
EPS	-2.30	2.64	0.20	-0.60	0.80	-32.8%	0.89	1.24	—	54.7%
Shares	—	69.7M	70.5M	72.5M	76.3M	+9.5%	—	—	—	—
Debt	—	5.9M	12.3M	9.9M	9.5M	17.1%	9.0M	—	—	—
Equity	—	396.1M	438.8M	438.4M	567.6M	12.7%	—	—	—	—
Op CF	—	5.8M	13.3M	25.7M	138.0M	187.5%	165.9M	—	—	—
Inv CF	—	-8.1M	-29.6M	37.7M	-189.0M	—	—	—	—	—
Fin CF	—	2.5M	1.5M	12.3M	33.0M	—	—	—	—	—

Loading 1Y...

PRICE (1Y)+22.4%

SMA 50SMA 200

$63.53

RSI (14)

39.2

52W High

$67.53

From 52W High

0.9%

SCORE BREAKDOWN

Quality

ROIC

12.4%80.3

ROE

13.7%80.0

GP/Assets

54.0%90.1

Op. Margin

13.7%73.4

FCF/Assets

15.4%93.7

Piotroski

783.4

Int. Cover

50.0x88.8

D/E Ratio

0.01x81.7

Current Ratio

3.79x62.8

Value

P/E (TTM)

70.3x14.0

EV/EBITDA

45.9x11.8

P/FCF

41.1x31.2

P/B

7.6x16.1

P/S

6.4x35.0

Div Yield

—N/A

Momentum

52W High %

94%92.8

RS 6M

43%92.6

SMA 50/200

1.21x89.6

EPS Rev 4W

-3.1%12.5

EPS Rev 12W

+15.3%90.4

EPS Improve

+91%71.1

Q Growth

165%90.0

FUNDAMENTALS

Market Cap

$4.8B

P/E (Forward)

36.8x

Gross Margin

54.7%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of KNSA are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
KNSA	Kiniksa Pharmaceuticals International, plc(you)	$4.8B	87	STRONG BUY
HIK.L	Hikma Pharmaceuticals PLC	$4.3B	89	STRONG BUY
HLN	Haleon plc	$43.1B	87	STRONG BUY
ANCR.L	Animalcare Group plc	$302M	90	STRONG BUY
EAH.L	ECO Animal Health Group plc	$78M	95	STRONG BUY
LIVN	LivaNova PLC	$4.3B	80	BUY
SN.L	Smith & Nephew plc	$12.7B	85	STRONG BUY
AGY.L	Allergy Therapeutics plc	$630M	4	STRONG SELL
CTEC.L	Convatec Group PLC	$5.5B	65	BUY
SPI.L	Spire Healthcare Group plc	$1.1B	82	STRONG BUY

Peer medians: ROE -3.8% · P/E 24.4x · Gross margin 56.9%

Kiniksa Pharmaceuticals International, plc (KNSA) — Stock Score Summary

Kiniksa Pharmaceuticals International, plc (KNSA) has a MoatMap StockRank of 87/100 based on Quality (83/100), Value (20/100), and Momentum (79/100) factor scores. The current signal is STRONG BUY. Kiniksa Pharmaceuticals has strong quality Q83 and momentum M83, but value at V20 is the lowest in this batch and far below the calibrated floor. Insider selling of 0.23% is separately adverse.

Key Financial Metrics

Price	$63.53
Market Cap	$4.8B
P/E (TTM)	70.31
P/E (Forward)	36.76
Price/Book	7.61
Return on Equity	13.7%
Return on Invested Capital	12.4%
Debt/Equity	0.01x
Gross Margin	54.7%
Operating Margin	13.7%
Revenue Growth	55.5%
Free Cash Flow	$118M

Kiniksa Pharmaceuticals International, plc operates in the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector (United Kingdom).

Frequently Asked Questions

What is Kiniksa Pharmaceuticals International, plc’s (KNSA) StockRank?: MoatMap’s StockRank for Kiniksa Pharmaceuticals International, plc (KNSA) is 87/100, with a Strong Buy signal. It is a composite of Quality (83), Value (20), and Momentum (79) factor ranks across MoatMap’s 20,000+ stock universe.
Does Kiniksa Pharmaceuticals International, plc have an economic moat?: Kiniksa Pharmaceuticals International, plc (KNSA) has a Quality factor score of 83/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Kiniksa Pharmaceuticals International, plc a buy, hold, or sell?: MoatMap’s current signal for Kiniksa Pharmaceuticals International, plc (KNSA) is Strong Buy, based on a StockRank of 87/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Kiniksa Pharmaceuticals International, plc in?: Kiniksa Pharmaceuticals International, plc (KNSA) operates in the Healthcare sector, specifically the Drug Manufacturers - Specialty & Generic industry (United Kingdom).